

PharmaMar has presented results of its antitumor compounds trabectedin and plocabulin at the CTOS Congress

- PharmaMar had a notable presence at CTOS with two oral presentations and six posters on trabectedin and two posters on plocabulin.
- CTOS was held in Tokyo, Japan, from November 13th to 16th.

Madrid, November 18th, 2019. – PharmaMar (MSE:PHM) announces that the results of clinical and pre-clinical studies on Yondelis® (trabectedin) and plocabulin (PM184), compounds of a marine origin, have been presented at the International Congress of the Connective Tissue Oncological Society (CTOS). The Congress was held in Tokyo, Japan, from 13th to 16th November.

This year, PharmaMar compounds have had a notable presence. Trabectedin had two oral presentations and six posters. The most noteworthy of these presentations was an oral presentation by Dr. Martinez-Trufero, medical oncologist at Hospital Universitario Miguel Servet in Zaragoza, Spain, entitled "*Validation of GEISTRA score: a predictive tool of trabectedin (tb) benefit in Advanced Soft Tissue Sarcomas (ASTS), based on Growth Modulation Index (GMI). A retrospective registry-based analysis from Spanish Group of Sarcoma Research (GEIS)*". The objective of this trial was to validate the GEISTRA score system as a predictive tool for the benefit of trabectedin in patients with Soft Tissue Sarcoma. After the study, the GEISTRA score system has been validated as a useful tool for selecting the clinical profile of patients who may be the best candidates to be treated with trabectedin.

Also with trabectedin, Dr. Martín Broto, medical oncologist at the Hospital Universitario Virgen del Rocío in Seville, Spain, presented the poster "*Trabectedin with concurrent low-dose of radiation therapy for metastatic soft tissue sarcomas: A multicenter European, single arm phase II trial of Spanish, French and Italian sarcoma groups*" with the results of a single-arm Phase II trial of trabectedin in combination with low-dose radiation therapy for the treatment of Soft Tissue Sarcoma, achieving its primary endpoint of Overall Response Rate (ORR), with 55.6% of responses to the treatment. These results were also presented at the last ESMO Congress, held in Barcelona, Spain, from September 27th to October 1st.

Dr. Yannick Wang, researcher at the Laboratory of Experimental Oncology (Department of Oncology) of the University Hospital of Leuven, Belgium, has also presented the results of the preclinical evaluation of the compound plocabulin (PM184), performed in animal models of different types of sarcoma. The results of these experiments demonstrate the antitumor activity of plocabulin also surpasses that of the established standard treatment, doxorubicin. These results, therefore, justify the possibility of exploring the activity of the compound in clinical trials.

Main studies presented at the CTOS Congress

Trabectedin:

- **Validation of GEISTRA score: a predictive tool of trabectedin (tb) benefit in Advanced Soft Tissue Sarcomas (ASTS), based on Growth Modulation Index (GMI). A retrospective registry-based analysis from Spanish Group of Sarcoma Research (GEIS).**

Lead Author: Javier Martinez-Trufero.

- **Trabectedin with concurrent low-dose of radiation therapy for metastatic soft tissue sarcomas: A multicenter European, single arm phase II trial of Spanish, French and Italian sarcoma groups.**

Lead Author: Javier Martin-Broto

- **First interim results from a German retrospective study of sarcoma patients treated with trabectedin (RETRASARC).**

Lead Author: Bernd Kasper

- **Efficacy and safety of trabectedin for patients with unresectable and relapsed Soft Tissue Sarcoma in Japan: a Japanese Musculoskeletal Oncology Group (JMOG) study.**

Lead Author: Kobayashi

- **A Phase III randomised controlled trial comparing histotype-tailored neoadjuvant chemotherapy and standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): a Sarculator-based prognostic risk stratification analysis.**

Lead Author: Pasquali Sandro.

- **Italian Sarcoma Group (ISG) - Spanish Sarcoma Group (GEIS) - French Sarcoma Group (FSG) - Polish Sarcoma Group (PSG) clinical trial on neo-adjuvant chemotherapy in high-risk soft tissue sarcomas (STS): results of non-randomized group of patients.**

Lead Author: Elena Palassini.

- **Preliminary data on a Phase 2 study on trabectedin (t) in advanced retroperitoneal leiomyosarcoma and well differentiated/dedifferentiated liposarcoma (travell).**

Lead Author: Sanfilippo

- **GLO1 as novel potential target to overcome trabectedin resistance in Soft Tissue Sarcomas.**

Lead Author: Francesco Pantano

Plocabulin (PM184):

- **Plocabulin, a novel tubulin inhibitor, has antitumor activity in a patient-derived xenograft (PDX) model of dedifferentiated liposarcoma.**

Lead Author: Yannick Wang

- **Plocabulin, a novel tubulin inhibitor, has antitumor activity in a patient-derived xenograft (PDX) model of CIC-rearranged sarcoma.**

Lead Author: Yannick Wang

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several

types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

About Yondelis®

Yondelis® (trabectedin) is a novel, synthetically produced antitumor agent originally isolated from *Ecteinascidia turbinata*, a type of sea squirt. Yondelis® exerts its anticancer effects primarily by inhibiting active transcription, a type of gene expression on which proliferating cancer cells are particularly dependent.

About plocabulin (PM184)

PM184 is a marine-derived synthetic drug originally isolated from the sponge *Lithoplocamia lithistoides*. This drug candidate targets a protein called tubulin in a novel way, inhibiting its polymerization to form the skeleton of the cell. PM184 blocks cancer growth by impairing the division of tumor cells.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000

Investor Relations:

José Luis Moreno Martínez-Losa – Capital Markets & Investor Relations Director
investorrelations@pharmamar.com
Phone: +34 914444500



Or please visit our website at www.pharmamar.com